Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4C7E6)

• Drug Name: BAICALEIN Drug Info
• Synonyms: baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Noroxylin; Biacalein; BaiKalein; Baicelein; UNII-49QAH60606; NSC661431; NSC 661431; CHEMBL8260; 5,6,7-trihydroxy-2-phenylchromen-4-one; CHEBI:2979; FXNFHKRTJBSTCS-UHFFFAOYSA-N; MFCD00017459; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; 49QAH60606; 5,7-Trihydroxyflavone; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; AC1NQYPP; Tocris-1761

Indication

Disease Entry	ICD 11	Status	REF
Influenza virus infection	1E30-1E32	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 5281605
  ChEBI ID: CHEBI:2979
  CAS Number: CAS 491-67-8
  TTD Drug ID: DM4C7E6

Molecule-Related Drug Atlas

Drug(s) Targeting Arachidonate 5-lipoxygenase (5-LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zileuton	DMVRIC2	Asthma	CA23	Approved	[8]
Diethylcarbamazine	DM1TJ8F	Lymphatic filariasis	1F66.3	Approved	[9]
Silymarin	DMXBYQR	N. A.	N. A.	Phase 4	[10]
3,4-Dihydroxycinnamic Acid	DMVZL26	Thrombocytopenia	3B64	Phase 4	[11]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[12]
ABT-761	DM3FIC2	Asthma	CA23	Phase 3	[13]
Tenidap	DMHQRYE	Rheumatoid arthritis	FA20	Phase 3	[14]
FPL-62064	DMGF8MZ	Inflammation	1A00-CA43.1	Phase 3	[15]
Flobufen	DMPSG4D	Rheumatoid arthritis	FA20	Phase 3	[16]
Darbufelone	DMYVKM5	Asthma	CA23	Phase 2/3	[17]

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[18]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[19]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[20]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[21]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[22]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[23]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[24]
SMART anti-E/P selectin	DMC49KO	Asthma	CA23	Discontinued in Phase 1	[25]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[26]
PURPUROGALLIN	DM63O4F	N. A.	N. A.	Terminated	[3]

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Multiple myeloma	2A83	Approved	[27]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[28]
Pentoxifylline	DMU3DNC	Intermittent claudication	BD40.00	Approved	[29]
Lenalidomide	DM6Q7U4	Multiple myeloma	2A83	Approved	[30]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[31]
Golimumab	DMHZV7X	Rheumatoid arthritis	FA20	Approved	[32]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[33]
Etanercept	DMCV109	Arthritis	FA20	Approved	[34]
Adalimumab	DMQMV1B	Rheumatoid arthritis	FA20	Approved	[35]
Infliximab	DMH7OIA	Plaque psoriasis	EA90.0	Approved	[36]

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Hyperuricaemia	5C55.Y	Approved	[37]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[38]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[39]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[40]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[41]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[42]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[43]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[44]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[45]
Fused heterocyclic compound 3	DM2QVHY	N. A.	N. A.	Patented	[45]

Drug(s) Targeting L-selectin (SELL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[19]
PURPUROGALLIN	DM63O4F	N. A.	N. A.	Terminated	[3]
Hu Dreg 55	DMK1VHF	Psoriasis vulgaris	EA90	Terminated	[46]
2,3,4-trihydroxybenzoic acid	DMWHK35	Discovery agent	N.A.	Investigative	[3]
LD201t1	DMC5XQ6	Inflammation	1A00-CA43.1	Investigative	[47]

Drug(s) Targeting Prolyl endopeptidase (PREP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALV-003	DMXSFA0	Coeliac disease	DA95	Phase 2	[48]
ONO-1603	DMKIZAL	Cognitive impairment	6D71	Phase 2	[49]
S-17092-1	DMYR1K8	Cognitive impairment	6D71	Phase 1	[50]
JTP-4819	DMI0UJS	Cognitive impairment	6D71	Discontinued in Phase 2	[51]
Z-321	DMLO2QY	Parkinson disease	8A00.0	Discontinued in Phase 1	[52]
Baicalin	DMY1TLZ	Human immunodeficiency virus infection	1C62	Terminated	[53]
Y-29794	DMLAVES	N. A.	N. A.	Terminated	[53]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[54]
Monothioglycerol	DMENSOZ	Discovery agent	N.A.	Investigative	[54]
Z-Pro-Prolinal	DM43O2U	Discovery agent	N.A.	Investigative	[55]

Drug(s) Targeting Lactoylglutathione lyase (GLO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Naringenin	DMHAZLM	N. A.	N. A.	Phase 1	[4]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[56]
Kaempferol	DMHEMUB	Discovery agent	N.A.	Investigative	[4]
S-(N-butyl-N-hydroxycarbamoyl)glutathione	DMU7EQV	Discovery agent	N.A.	Investigative	[57]
S-(N-heptyl-N-hydroxycarbamoyl)glutathione	DMV6T1Q	Discovery agent	N.A.	Investigative	[57]
S-(N-propyl-N-hydroxycarbamoyl)glutathione	DMRFKZ6	Discovery agent	N.A.	Investigative	[57]
S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione	DM1AHIW	Discovery agent	N.A.	Investigative	[56]
S-(N-pentyl-N-hydroxycarbamoyl)glutathione	DM4E9J2	Discovery agent	N.A.	Investigative	[57]
S-(N-methyl-N-hydroxycarbamoyl)glutathione	DM1C9W3	Discovery agent	N.A.	Investigative	[57]
S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione	DM3FXPV	Discovery agent	N.A.	Investigative	[57]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Inhibitor	[2]
L-selectin (SELL)	TT2IYXF	LYAM1_HUMAN	Inhibitor	[3]
Lactoylglutathione lyase (GLO1)	TTV9A7R	LGUL_HUMAN	Inhibitor	[4]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[3]
Prolyl endopeptidase (PREP)	TTNGKET	PPCE_HUMAN	Inhibitor	[5]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[6]
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[7]

References

• [1] ClinicalTrials.gov (NCT03830684) A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase IIa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever. U.S. National Institutes of Health.
• [2] Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36.
• [3] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [4] Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
• [5] Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24.
• [6] Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8.
• [7] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [8] 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
• [9] Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
• [10] Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
• [11] Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
• [12] Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
• [13] Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
• [14] The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
• [15] FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
• [16] Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
• [17] Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
• [18] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [19] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [20] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [21] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [22] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [23] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [24] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [25] HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res. 2002 Nov 15;91(10):907-14.
• [26] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [27] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [28] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [29] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [30] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [31] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [32] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [33] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [34] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [35] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [36] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [37] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [38] Clinical pipeline report, company report or official report of Takeda (2009).
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [40] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [41] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [42] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [43] Clinical pipeline report, company report or official report of Teijin Pharma.
• [44] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [45] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [46] Clinical pipeline report, company report or official report of glycomimetics.
• [47] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
• [48] The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95.
• [49] ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4.
• [50] Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29.
• [51] A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51.
• [52] Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav Brain Res. 1997 Feb;83(1-2):213-6.
• [53] Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38.
• [54] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [55] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [56] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [57] Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.